These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 12869356

  • 21. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.
    Labinjoh C, Newby DE, Pellegrini MP, Johnston NR, Boon NA, Webb DJ.
    J Am Coll Cardiol; 2001 Nov 01; 38(5):1402-8. PubMed ID: 11691515
    [Abstract] [Full Text] [Related]

  • 22. Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients.
    Giannarelli C, Virdis A, De Negri F, Magagna A, Duranti E, Salvetti A, Taddei S.
    Circulation; 2009 Mar 31; 119(12):1625-33. PubMed ID: 19289643
    [Abstract] [Full Text] [Related]

  • 23. Direct vascular effects of protease-activated receptor type 1 agonism in vivo in humans.
    Gudmundsdóttir IJ, Megson IL, Kell JS, Ludlam CA, Fox KA, Webb DJ, Newby DE.
    Circulation; 2006 Oct 10; 114(15):1625-32. PubMed ID: 17015787
    [Abstract] [Full Text] [Related]

  • 24. Tissue plasminogen activator genetic polymorphisms do not influence tissue plasminogen activator release in patients with coronary heart disease.
    Robinson SD, Ludlam CA, Boon NA, Newby DE.
    J Thromb Haemost; 2006 Oct 10; 4(10):2262-9. PubMed ID: 16836660
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
    Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE.
    Hypertension; 2004 Dec 10; 44(6):913-8. PubMed ID: 15492133
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Reactive hyperemia and tissue-type plasminogen activator release in hypertensive men.
    Dell'Omo G, De Negri F, Carmassi F, Ruocco L, Mariani M, Pedrinelli R.
    Blood Coagul Fibrinolysis; 2003 Jan 10; 14(1):19-25. PubMed ID: 12544724
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Intra-arterial vasopressin in the human forearm: pharmacodynamics and the role of nitric oxide.
    Affolter JT, McKee SP, Helmy A, Jones CR, Newby DE, Webb DJ.
    Clin Pharmacol Ther; 2003 Jul 10; 74(1):9-16. PubMed ID: 12844130
    [Abstract] [Full Text] [Related]

  • 33. Sympathoadrenal activation and muscarinic receptor stimulation induce acute release of tissue-type plasminogen activator but not von Willebrand factor across the human forearm.
    Jern C, Selin L, Tengborn L, Jern S.
    Thromb Haemost; 1997 Aug 10; 78(2):887-91. PubMed ID: 9268190
    [Abstract] [Full Text] [Related]

  • 34. In vivo release of tissue-type plasminogen activator across the human forearm during mental stress.
    Jern C, Selin L, Jern S.
    Thromb Haemost; 1994 Aug 10; 72(2):285-91. PubMed ID: 7831666
    [Abstract] [Full Text] [Related]

  • 35. Big endothelin-3 constricts forearm resistance vessels but not hand veins in humans.
    Ferro CJ, Strachan FE, Shepherd E, Haynes WG, Webb DJ.
    Clin Pharmacol Ther; 2000 Jul 10; 68(1):67-74. PubMed ID: 10945317
    [Abstract] [Full Text] [Related]

  • 36. Block of inward rectifying K+ channels (KIR) inhibits bradykinin-induced vasodilatation in human forearm resistance vasculature.
    Dwivedi R, Saha S, Chowienczyk PJ, Ritter JM.
    Arterioscler Thromb Vasc Biol; 2005 Feb 10; 25(2):e7-9. PubMed ID: 15591222
    [Abstract] [Full Text] [Related]

  • 37. Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men.
    Chia S, Ludlam CA, Fox KA, Newby DE.
    J Am Coll Cardiol; 2003 Jan 15; 41(2):333-9. PubMed ID: 12535831
    [Abstract] [Full Text] [Related]

  • 38. The contribution of nitric oxide and vasodilatory prostanoids to bradykinin-mediated vasodilation in Type 1 diabetes.
    Wotherspoon F, Browne DL, Meeking DR, Allard SE, Munday LJ, Shaw KM, Cummings MH.
    Diabet Med; 2005 Jun 15; 22(6):697-702. PubMed ID: 15910619
    [Abstract] [Full Text] [Related]

  • 39. Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm.
    Wilsdorf T, Gainer JV, Murphey LJ, Vaughan DE, Brown NJ.
    Hypertension; 2001 Apr 15; 37(4):1136-40. PubMed ID: 11304515
    [Abstract] [Full Text] [Related]

  • 40. MEN16132, a novel potent and selective nonpeptide kinin B2 receptor antagonist: in vivo activity on bradykinin-induced bronchoconstriction and nasal mucosa microvascular leakage in anesthetized guinea pigs.
    Valenti C, Cialdai C, Giuliani S, Lecci A, Tramontana M, Meini S, Quartara L, Maggi CA.
    J Pharmacol Exp Ther; 2005 Nov 15; 315(2):616-23. PubMed ID: 16027229
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.